Compare TBBK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | MLYS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2005 | 2023 |
| Metric | TBBK | MLYS |
|---|---|---|
| Price | $66.98 | $26.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $69.00 | $48.67 |
| AVG Volume (30 Days) | 403.2K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 37.43 |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $46.62 | ★ N/A |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $50.29 | $12.59 |
| 52 Week High | $81.65 | $47.65 |
| Indicator | TBBK | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 45.70 |
| Support Level | $66.21 | $26.01 |
| Resistance Level | $71.69 | $31.26 |
| Average True Range (ATR) | 1.97 | 1.23 |
| MACD | -0.30 | -0.17 |
| Stochastic Oscillator | 57.62 | 13.68 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.